ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) was down 1.2% during mid-day trading on Thursday . The company traded as low as $6.33 and last traded at $6.40. Approximately 145,504 shares traded hands during trading, a decline of 37% from the average daily volume of 231,594 shares. The stock had previously closed at $6.48.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on SPRY. SVB Leerink initiated coverage on ARS Pharmaceuticals in a report on Tuesday, December 13th. They issued an "outperform" rating and a $14.00 price target for the company. William Blair began coverage on ARS Pharmaceuticals in a research note on Tuesday, January 3rd. They issued an "outperform" rating and a $17.00 target price for the company.
Get ARS Pharmaceuticals alerts:ARS Pharmaceuticals Price Performance
The stock's fifty day moving average is $7.29. The company has a market cap of $230.77 million, a PE ratio of -2.64 and a beta of 0.20.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.57 EPS for the current fiscal year.Insider Buying and Selling at ARS Pharmaceuticals
In other news, CFO Kathleen D. Scott acquired 8,250 shares of the business's stock in a transaction dated Tuesday, November 29th. The shares were bought at an average cost of $6.24 per share, for a total transaction of $51,480.00. Following the acquisition, the chief financial officer now directly owns 8,250 shares in the company, valued at approximately $51,480. The purchase was disclosed in a filing with the SEC, which is available through this link. 34.40% of the stock is owned by company insiders.
ARS Pharmaceuticals Company Profile
(Get Rating)
ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Featured Articles
- Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.